TY - JOUR
AU - Kennedy, Nicholas A.
AU - Goodhand, James R.
AU - Bewshea, Claire
AU - Nice, Rachel
AU - Chee, Desmond
AU - Lin, Simeng
AU - Chanchlani, Neil
AU - Butterworth, Jeffrey
AU - Cooney, Rachel
AU - Croft, Nick
AU - Hart, Ailsa
AU - Irving, Peter M
AU - Kok, Klaartje B.
AU - Lamb, Christopher A.
AU - Limdi, Jimmy K.
AU - MacDonald, Jonathan
AU - McGovern, Dermot PB
AU - Mehta, Shameer
AU - Murray, Charles D.
AU - Patel, Kamal
AU - Pollok, Richard
AU - Raine, Tim
AU - Russell, Richard K
AU - Selinger, Christian
AU - Smith, Philip J
AU - Bowden, Jack
AU - McDonald, Timothy J.
AU - Lees, Charlie W
AU - Sebastian, Shaji
AU - Powell, Nick
AU - Ahmad, Tariq
PY - 2021
DA - March
TI - Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
JO - Gut
EP - 875
VL - 70
IS - 5
DO - http://dx.doi.org/10.1136/gutjnl-2021-324388
AB - OBJECTIVE: Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections.
PB - BMJ Publishing Group
UR - https://www.research.ed.ac.uk/en/publications/1bfd49d0-2ff9-4251-9b80-3c64409dface
KW - Coronavirus (COVID-19)
KW - Hospital care
ER